Anti-tumour effect of tocilizumab for osteosarcoma cell lines

Bone & Joint Research

article

Tomohito Hagi¹  Tomoki Nakamura¹  Kouji Kita¹  Takahiro Iino¹  Kunihiro Asanuma¹  Akihiro Sudo¹ 

[1] Department of Orthopaedic Surgery, Mie University Graduate School of Medicine

关键词: Osteosarcoma;    Tocilizumab;    Anti-tumour effect;    Interleukin-6;    Interleukin-6 receptor;   

DOI  :  10.1302/2046-3758.911.BJR-2020-0123.R1

学科分类：骨科学

来源: British Editorial Society Of Bone And Joint Surgery

【 摘 要 】

AimsTocilizumab, an interleukin-6 (IL-6) receptor (IL-6R) targeting antibody, enhances the anti-tumour effect of conventional chemotherapy in preclinical models of cancer. We investigated the anti-tumour effect of tocilizumab in osteosarcoma (OS) cell lines.MethodsWe used the 143B, HOS, and Saos-2 human OS cell lines. We first analyzed the IL-6 gene expression and IL-6Rα protein expression in OS cells using reverse transcription real time quantitative-polymerase chain reaction (RT-qPCR) analysis and western blotting, respectively. We also assessed the effect of tocilizumab on OS cells using proliferation and invasion assay.ResultsThe OS cell lines 143B, HOS, and Saos-2 expressed IL-6R. Recombinant human IL-6 treatment increased proliferation of 143B and HOS cells. Tocilizumab treatment decreased proliferation and invasion of 143B, HOS, and Saos-2.ConclusionIn conclusion, we confirmed the production of IL-6 and the expression of IL-6R in OS cells and demonstrated that tocilizumab inhibits proliferation and invasion in OS cells.

【 授权许可】

CC BY-NC